Valuation: SpectraCure AB

Market Cap 29.39M 3.05M 2.66M 2.46M 2.27M 4.27M 294M 4.37M 11.56M 144M 11.45M 11.2M 495M P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value 18.65M 1.93M 1.69M 1.56M 1.44M 2.71M 186M 2.77M 7.34M 91.26M 7.27M 7.11M 314M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
28.39%
Yield 2024 *
-
Yield 2025 -
1 day+26.54%
1 week+3.21%
Current month-6.36%
1 month+4.04%
3 months-26.43%
6 months-51.32%
Current year-66.94%
1 week 0.04
Extreme 0.0385
0.07
1 month 0.04
Extreme 0.0385
0.09
Current year 0.04
Extreme 0.0385
0.17
1 year 0.04
Extreme 0.0385
0.32
3 years 0.04
Extreme 0.0385
6.13
5 years 0.04
Extreme 0.0385
12
10 years 0.04
Extreme 0.0385
45.15
Manager TitleAgeSince
Chief Executive Officer 54 2025-09-30
Director of Finance/CFO - 2026-05-31
Chief Tech/Sci/R&D Officer - 2025-10-06
Director TitleAgeSince
Director/Board Member 63 2012-08-30
Director/Board Member 72 2021-12-31
Chairman 74 2021-12-31
Date Insider Type Main position Quantity % Market Cap.
5/26/23 Buy

Chairman

25,000 0.0257%
8/30/22 Buy

Director

25,000 0.0257%
7/9/22 Buy

Director

1,048,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
+26.54%+3.21%-70.54%-99.15% 3.05M
-1.33%+0.12%+39.59%+51.90% 1.5B
0.00%-6.96%-47.81%-53.33% 267M
0.00%-1.92%+24.39%-13.56% 53.82M
-1.36%-2.69%-11.07%-51.13% 52.75M
Average +4.77%-1.65%-13.09%-33.05% 375.32M
Weighted average by Cap. -1.06%-1.02%+25.14%+31.94%

Financials

2024 2025
Net sales - -
Net income -23M -2.39M -2.09M -1.92M -1.77M -3.34M -230M -3.42M -9.05M -113M -8.96M -8.77M -388M -56.08M -5.82M -5.08M -4.69M -4.32M -8.15M -560M -8.33M -22.06M -274M -21.85M -21.37M -945M
Net Debt -13.13M -1.36M -1.19M -1.1M -1.01M -1.91M -131M -1.95M -5.16M -64.24M -5.12M -5M -221M -10.74M -1.11M -973K -898K -828K -1.56M -107M -1.6M -4.22M -52.53M -4.18M -4.09M -181M
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
26-07-17 SEK 0.0515 +26.54% 5,399,820
26-07-16 SEK 0.0407 -9.96% 2,448,460
26-07-15 SEK 0.0452 -3.42% 1,019,296
26-07-14 SEK 0.0468 -2.70% 2,019,473
26-07-13 SEK 0.0481 -3.61% 2,551,065
  1. Stock Market
  2. Stocks
  3. SPEC Stock